The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Poordad, F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010494 · Cited by 2,520
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., Marcellin, P., Muir, A. J., Ferenci, P., Flisiak, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012912 · Cited by 2,398
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bacon, B. R., Gordon, S. C., Lawitz, E., Marcellin, P., Vierling, J. M., Zeuzem, S., Poordad, F., Goodman, Z. D., Sings, H. L., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009482 · Cited by 1,626
Telaprevir for Retreatment of HCV Infection
Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S., Focaccia, R., Younossi, Z., Foster, G. R., Horban, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013086 · Cited by 1,546
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
Smith, D. B., Bukh, J., Kuiken, C., Muerhoff, S. A., Rice, C. M., Stapleton, J. T., & Simmonds, P. (2014) · Hepatology · doi:10.1002/hep.26744 · Cited by 1,353
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A. S., Hinestrosa, F., Thuluvath, P. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306218 · Cited by 1,190
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939
MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis
Tsai, W.-C., Hsu, S.-D., Hsu, C.-S., Lai, T.-C., Chen, S.-J., Shen, R., Huang, Y., Chen, H.-C., Lee, C.-H., Tsai, T.-F., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63455 · Cited by 814
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Symonds, W. T., Hindes, R. G., & Berrey, M. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208953 · Cited by 764
Hézode, C., Fontaine, H., Dorival, C., Larrey, D. G., Zoulim, F., Canva, V., de Lédinghen, V., Poynard, T., Samuel, D., Bourlière, M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.035 · Cited by 443
Self-citationGuedj, J., Dahari, H., Rong, L., Sansone, N. D., Nettles, R. E., Cotler, S. J., Layden, T. J., Uprichard, S. L., & Perelson, A. S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203110110 · Cited by 339
Koh, C., Li, Q., & Liang, J. (2016) · Clinical Virology · doi:10.1128/9781555819439.ch54 · Cited by 321
Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus
Pawlotsky, J.-M. (2011) · Hepatology · doi:10.1002/hep.24262 · Cited by 311
Self-citationLink, J. O., Taylor, J. G., Xu, L., Mitchell, M., Guo, H., Liu, H., Kato, D., Kirschberg, T., Sun, J., Squires, N., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401499g · Cited by 295
Osinusi, A., Meissner, E. G., Lee, Y.-J., Bon, D., Heytens, L., Nelson, A., Sneller, M., Kohli, A., Barrett, L., Proschan, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.109309 · Cited by 291
Summa, V., Ludmerer, S. W., McCauley, J. A., Fandozzi, C., Burlein, C., Claudio, G., Coleman, P. J., DiMuzio, J. M., Ferrara, M., Di Filippo, M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-12 · Cited by 259
Hepatitis C Virus RNA Replication
Lohmann, V. (2013) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-27340-7_7 · Cited by 213
Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor
Rosenquist, Å., Samuelsson, B., Johansson, P.-O., Cummings, M. D., Lenz, O., Raboisson, P., Simmen, K., Vendeville, S., de Kock, H., Nilsson, M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401507s · Cited by 213
Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype Activity
Coburn, C. A., Meinke, P. T., Chang, W., Fandozzi, C. M., Graham, D. J., Hu, B., Huang, Q., Kargman, S., Kozlowski, J., Liu, R., et al. (2013) · ChemMedChem · doi:10.1002/cmdc.201300343 · Cited by 201
McPhee, F., Sheaffer, A. K., Friborg, J., Hernandez, D., Falk, P., Zhai, G., Levine, S., Chaniewski, S., Yu, F., Barry, D., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01186-12 · Cited by 188
Zeisel, M. B., Felmlee, D. J., & Baumert, T. F. (2013) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-27340-7_4 · Cited by 179
Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
McCauley, J. A., McIntyre, C. J., Rudd, M. T., Nguyen, K. T., Romano, J. J., Butcher, J. W., Gilbert, K. F., Bush, K. J., Holloway, M. K., Swestock, J., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9015526 · Cited by 178
Ruane, P. J., Ain, D., Stryker, R., Meshrekey, R., Soliman, M., Wolfe, P. R., Riad, J., Mikhail, S., Kersey, K., Jiang, D., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.044 · Cited by 167
Jiang, Y., Andrews, S. W., Condroski, K. R., Buckman, B. O., Serebryany, V., Wenglowsky, S., Kennedy, A. L., Madduru, M. R., Wang, B., Lyon, M. A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400164c · Cited by 152
Hepatitis C Virus RNA Translation
Niepmann, M. (2013) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-27340-7_6 · Cited by 149
Lindenbach, B. D. (2013) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-27340-7_8 · Cited by 141
Hopkins, S., Scorneaux, B., Huang, Z., Murray, M. G., Wring, S. A., Smitley, C., Harris, R. W., Erdmann, F., Fischer, G. S., & Ribeill, Y. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00660-09 · Cited by 139
Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A
DeGoey, D. A., Randolph, J. T., Liu, D., Pratt, J. K., Hutchins, C. W., Donner, P., Krueger, A. C., Matulenko, M. A., Patel, S. V., Motter, C. E., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401398x · Cited by 131
White, P. W., Llinàs‐Brunet, M., Amad, M., Bethell, R. C., Bolger, G. T., Cordingley, M. G., Duan, J., Garneau, M., Lagacé, L., Thibeault, D., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00787-10 · Cited by 113
Gentles, R. G., Ding, M., Bender, J. A., Bergstrom, C. P., Grant-Young, K. A., Hewawasam, P., Hudyma, T. W., Martin, S. W., Nickel, A., Regueiro‐Ren, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4016894 · Cited by 103
Llinàs‐Brunet, M., Bailey, M. D., Goudreau, N., Bhardwaj, P. K., Bordeleau, J., Bös, M., Bousquet, Y., Cordingley, M. G., Duan, J., Forgione, P., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100690x · Cited by 93
Discovery of GS-9451: An acid inhibitor of the hepatitis C virus NS3/4A protease
Sheng, X. C., Appleby, T. C., Butler, T., Cai, R. Z., Chen, X., Cho, A., Clarke, M. O., Cottell, J. J., Delaney, W. E., Doerffler, E. M., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.017 · Cited by 43
Cummings, M. D., Lin, T., Hu, L., Tahri, A., McGowan, D. C., Amssoms, K., Last, S., Devogelaere, B., Rouan, M. C., Vijgen, L., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401396p · Cited by 39
Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451
Yang, H., Robinson, M. F., Corsa, A. C., Peng, B., Cheng, G., Yang, T., Wang, Y., Pakdaman, R., Shen, M., Qi, X., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00487-13 · Cited by 32
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
EASL Recommendations on Treatment of Hepatitis C 2015
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.025 · Cited by 1,156
EASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082
HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B
Nassal, M. (2015) · Gut · doi:10.1136/gutjnl-2015-309809 · Cited by 899
Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 759
Metadata
- Authors
- Pawlotsky, J.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 146
- Issue
- 5
- Pages
- 1176-1192
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2148864053
- Cited by
- 518
- References
- 38
- FWCI
- 51.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.